Trial Profile
A Randomized, Double Blind, Parallel Group Study of the Efficacy and Safety of Mepolizumab as Adjunctive Therapy in Patients With Severe Asthma With Eosinophilic Inflammation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Acute asthma; Asthma
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 26 Feb 2024 Results of post-hoc anaylsis involving study of mepolizumab in patients with SA-EP, presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 24 May 2023 Primary endpoint has been met (Number of clinically significant exacerbations of asthma at week 52) , according to Results presented at the 119th International Conference of the American Thoracic Society
- 24 May 2023 Results reporting safety and efficacy outcomes data at week 52 presented at the 119th International Conference of the American Thoracic Society